Sintx Technologies (NASDAQ:SINT – Get Free Report) and Adynxx (OTCMKTS:ADYX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
This table compares Sintx Technologies and Adynxx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Sintx Technologies and Adynxx, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk & Volatility
Sintx Technologies has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Adynxx has a beta of 2.68, indicating that its stock price is 168% more volatile than the S&P 500.
Institutional & Insider Ownership
2.7% of Sintx Technologies shares are owned by institutional investors. 1.0% of Sintx Technologies shares are owned by insiders. Comparatively, 17.4% of Adynxx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Sintx Technologies and Adynxx’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sintx Technologies||$895,000.00||1.97||-$12.04 million||N/A||N/A|
Adynxx has lower revenue, but higher earnings than Sintx Technologies.
Adynxx beats Sintx Technologies on 5 of the 9 factors compared between the two stocks.
About Sintx Technologies
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Receive News & Ratings for Sintx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sintx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.